immunotherapy

Pliant Therapeutics presented Phase 1 data for PLN-101095 showing 89% average tumor reduction in ICI-refractory cancer patients, with Phase 1b expansion underway.

Theriva Biologics will present expanded VIRAGE trial data for VCN-01 at AACR 2026, with FDA and EMA agreement on Phase 3 design for metastatic pancreatic cancer treatment.

MoonLake Immunotherapeutics CEO Jorge Santos da Silva sold $2.8M in shares, reducing holdings 4.9%. Stock down 47% year-over-year amid disappointing trial results.

Acrivon highlights preclinical data for ACR-368 and ACR-2316 combination therapies at AACR 2026, showing synergies with checkpoint inhibitors and ADCs.

Immatics' PRAME-directed TCR therapy achieves deep remission in advanced pediatric cancer patient, validating engineered T-cell approach in solid tumors.

Over 100 pharmaceutical companies compete to develop 120+ NSCLC pipeline drugs, with 30+ in late-stage trials. Precision oncology advances drive innovation in biomarker-selected populations.

Immutep gains FDA orphan drug designation for eftilagimod alfa in soft tissue sarcoma, with Phase II trial results exceeding efficacy targets by 47%.

AIM ImmunoTech disclosed going concern warnings in 2025 audited statements but expressed confidence in fundraising backed by promising Ampligen-Imfinzi trial results.

Global allergy diagnostic market projected to reach $10.77B by 2030 from $6.80B in 2025, driven by technological advances and rising allergies.

ImmunityBio faces securities lawsuit after FDA warning letter regarding misleading efficacy claims for immunotherapy drug Anktiva, triggering 21% stock plunge.

Biotech hedge fund BVF Partners sold $63M in MoonLake shares, trimming its stake 78% while retaining 15.9M shares, amid broader sector volatility.

Evaxion completes Phase 2 extension of personalized cancer vaccine EVX-01 with 75% response rate and 92% durability at two years.

MiNK Therapeutics will present Phase II data on agenT-797 combined immunotherapy for PD-1 refractory gastroesophageal cancer at AACR 2026.

Kirby McInerney LLP filed securities fraud lawsuit against ImmunityBio over allegedly misleading Anktivas marketing. FDA warning letter triggered 21.2% stock decline.

Keymed Biosciences receives up to $320M from Gilead's acquisition of its immunotherapy spinoff Ouro Medicines, marking a landmark exit for Chinese biotech.

Adagene reports 29% response rate for ADG126 in colorectal cancer with improved safety profile. Company maintains $74.5M cash reserves extending runway into early 2028.

Merck partners with Infinimmune for next-gen antibody drugs, gaining exclusive rights to candidates from AI-powered platform with up to $838M in potential milestone payments.

Proleukin market projected to grow 6.1% annually to $1.68M by 2030, driven by rising cancer prevalence and expanded indications. Iovance Biotherapeutics strengthens position via 2023 acquisition.

Global bile duct cancer market projected to reach $3.89B by 2030 from $2.59B in 2025, driven by immunotherapy, AI diagnostics, and rising disease prevalence.

Esophageal cancer market projected to grow 44% to $2.37B by 2030 at 9.5% CAGR, with Pfizer, Roche, and Merck dominating through precision oncology and immunotherapy innovations.